Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? (Q38244078)

31 August 2017

title

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? (English)

1 reference

31 August 2017

0 references

Annie Killoran

1

1 reference

31 August 2017

Kevin M Biglan

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

27 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

29

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

1404-1413

1 reference

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease

31 August 2017

cites work

1 reference

Symptomatic treatment of Huntington disease

21 January 2018

1 reference

Treatment of Huntington's disease

21 January 2018

1 reference

Evidence based medicine: what it is and what it isn't

21 January 2018

1 reference

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Harnessing experience: exploring the gap between evidence-based medicine and clinical practice

21 January 2018

1 reference

An evidence-based approach in the treatment of Huntington's disease.

21 January 2018

1 reference

Therapeutics in Huntington's Disease

21 January 2018

1 reference

Treatment of huntington disease

21 January 2018

1 reference

Pharmacologic approaches to the treatment of Huntington's disease

21 January 2018

1 reference

Huntington's disease: clinical presentation and treatment

21 January 2018

1 reference

Advances in the Pharmacological Management of Huntingtonʼs Disease

21 January 2018

1 reference

The current clinical management of Huntington's disease

21 January 2018

1 reference

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

Commentary on the role of expert opinion in developing evidence-based guidelines

21 January 2018

1 reference

Does evidence-based medicine apply to psychiatry?

21 January 2018

1 reference

Evidence-based medicine in practice

21 January 2018

1 reference

Is evidence sufficient for evidence-based medicine?

21 January 2018

1 reference

EAU guidelines on surgical treatment of urinary incontinence.

21 January 2018

1 reference

Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update.

21 January 2018

1 reference

Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management

21 January 2018

1 reference

Position paper by Canadian dental sleep medicine professionals on the role of different health care professionals in managing obstructive sleep apnea and snoring with oral appliances

21 January 2018

1 reference

Clinical management of rivaroxaban-treated patients

21 January 2018

1 reference

ESHRE guideline: management of women with endometriosis.

21 January 2018

1 reference

Management of type 2 diabetes mellitus in children and adolescents

21 January 2018

1 reference

Evaluating treatments in health care: the instability of a one-legged stool

21 January 2018

1 reference

Physicians' and patients' choices in evidence based practice

21 January 2018

1 reference

Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

21 January 2018

1 reference

Rate and correlates of weight change in Huntington's disease

21 January 2018

1 reference

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

Behavioural abnormalities contribute to functional decline in Huntington's disease.

21 January 2018

1 reference

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

21 January 2018

1 reference

Huntington's disease: clinical correlates of disability and progression

21 January 2018

1 reference

Huntington's disease in Venezuela: neurologic features and functional decline

21 January 2018

1 reference

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals

21 January 2018

1 reference

Unawareness of motor phenoconversion in Huntington disease

21 January 2018

1 reference

Unawareness of dyskinesias in Parkinson's and Huntington's diseases

21 January 2018

1 reference

Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia.

21 January 2018

1 reference

Awareness of involuntary movements in Huntington disease

21 January 2018

1 reference

The long-term effect of tetrabenazine in the management of Huntington disease

21 January 2018

1 reference

Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort

21 January 2018

1 reference

Tetrabenazine: for chorea associated with Huntington's disease

21 January 2018

1 reference

A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

21 January 2018

1 reference

Rate of functional decline in Huntington's disease. Huntington Study Group

21 January 2018

1 reference

21 January 2018

1 reference

Suicidality in Huntington's disease

21 January 2018

1 reference

Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk

21 January 2018

1 reference

Earliest functional declines in Huntington disease

21 January 2018

1 reference

Aspiration pneumonia and death in Huntington's disease

21 January 2018

1 reference

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

21 January 2018

1 reference

Amantadine: the journey from fighting flu to treating Parkinson disease.

21 January 2018

1 reference

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study

21 January 2018

1 reference

A pilot study using nabilone for symptomatic treatment in Huntington's disease

21 January 2018

1 reference

Functional and motor response to low dose olanzapine in Huntington's disease: case report

21 January 2018

1 reference

Effectiveness of risperidone in Huntington chorea patients.

21 January 2018

1 reference

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

21 January 2018

1 reference

Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms

21 January 2018

1 reference

Risperidone in treatment of choreoathetosis of Huntington's disease

21 January 2018

1 reference

Riluzole and olanzapine in Huntington's disease

21 January 2018

1 reference

High-dose olanzapine in Huntington's disease

21 January 2018

1 reference

The use of olanzapine for movement disorder in Huntington's disease: a first case report

21 January 2018

1 reference

Olanzapine for Huntington's disease: an open label study

21 January 2018

1 reference

Olanzapine in Huntington's disease

21 January 2018

1 reference

Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report

21 January 2018

1 reference

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia

21 January 2018

1 reference

A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study.

21 January 2018

1 reference

Quetiapine in Huntington's disease: a first case report

21 January 2018

1 reference

Ziprasidone in Huntington's disease: the first case reports

21 January 2018

1 reference

Zotepine in Huntington's disease

21 January 2018

1 reference

Aripiprazole in the Treatment of Olanzapine-Resistant Psychotic and Motor Symptoms of Huntington’s Disease

21 January 2018

1 reference

Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease

21 January 2018

1 reference

Serum haloperidol concentration and choreiform movements in Huntington's disease

21 January 2018

1 reference

The gait abnormality of Huntington's disease

21 January 2018

1 reference

Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin).

21 January 2018

1 reference

Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea

21 January 2018

1 reference

Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease

21 January 2018

1 reference

Tiapride in 12 Huntington's disease patients

21 January 2018

1 reference

Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine

21 January 2018

1 reference

Efficacy of levetiracetam in Huntington disease

21 January 2018

1 reference

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

21 January 2018

1 reference

Levetiracetam-induced parkinsonism in a Huntington disease patient

21 January 2018

1 reference

Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort

21 January 2018

1 reference

21 January 2018

Treatment of myoclonus

1 reference

Weight change associated with antiepileptic drugs

21 January 2018

1 reference

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

21 January 2018

1 reference

New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine

21 January 2018

1 reference

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value

21 January 2018

1 reference

Bruxism in Huntington's disease

21 January 2018

1 reference

Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic — Rigid form

21 January 2018

1 reference

Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome

21 January 2018

1 reference

Levodopa responsive parkinsonism in an adult with Huntington's disease

21 January 2018

1 reference

Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease

21 January 2018

1 reference

Amantadine in the akinetic-rigid variant of Huntington's disease

21 January 2018

1 reference

Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.

21 January 2018

1 reference

Results of the citalopram to enhance cognition in Huntington disease trial

21 January 2018

1 reference

Fluoxetine in the treatment of Huntington's disease

21 January 2018

1 reference

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

21 January 2018

1 reference

Sertraline in the treatment of severe aggressiveness in Huntington's disease

21 January 2018

1 reference

Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders

21 January 2018

1 reference

Treatment of aggression in juvenile-onset Huntington's disease with buspirone

21 January 2018

1 reference

Mirtazapine in suicidal Huntington's disease

21 January 2018

1 reference

Improvement of Huntington's disease with olanzapine and valproate

21 January 2018

1 reference

Lamotrigine in motor and mood symptoms of Huntington's disease

21 January 2018

1 reference

Off label use of lithium in the treatment of Huntington's disease: A case series

21 January 2018

1 reference

Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea

21 January 2018

1 reference

Lithium treatment in patients with Huntington disease and suicidal behavior

21 January 2018

1 reference

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease.

21 January 2018

1 reference

Risperidone in chorea and psychosis of Huntington's disease

21 January 2018

1 reference

Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease

21 January 2018

1 reference

Forgotten frontal lobe syndrome or "Executive Dysfunction Syndrome".

21 January 2018

1 reference

ECT as a treatment for depression in Huntington's disease

21 January 2018

1 reference

ECT in genetically confirmed Huntington's disease

21 January 2018

1 reference

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

21 January 2018

1 reference

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

Donepezil for Huntington's disease

21 January 2018

1 reference

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

21 January 2018

1 reference

The effects of modafinil on mood and cognition in Huntington's disease

21 January 2018

1 reference

Rivastigmine in the treatment of Huntington's disease

21 January 2018

1 reference

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

EXIT, QED, and DSM-IV: very early Alzheimer's disease.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26014

1 reference

31 August 2017

1 reference